GSK plc (LON:GSK) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• GSK has a consensus “Hold” rating from eight analysts: five holds, two buys, and one sell. The average 12-month price target is GBX 2,064.38, above the stock’s GBX 1,853 opening price.
• Recent broker updates were mixed but generally neutral, with price targets ranging from GBX 1,975 at Royal Bank of Canada to GBX 2,500 at Jefferies, which maintained its “Buy” rating.
• GSK insiders purchased shares during the latest quarter, acquiring 2,144 shares valued at approximately $6.0 million. The company reported quarterly EPS of GBX 10.80 and has a market capitalization of roughly £74.25 billion.

Shares of GSK plc (LON:GSK - Get Free Report) have been assigned an average rating of "Hold" from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is GBX 2,064.38.

A number of brokerages have recently issued reports on GSK. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a GBX 2,000 price target on shares of GSK in a report on Tuesday. Berenberg Bank upped their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a "hold" rating in a report on Tuesday, September 15th. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and issued a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th.

Insider Activity at GSK

In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the business's stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal purchased 637 shares of the business's stock in a transaction on Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Over the last quarter, insiders have acquired 2,144 shares of company stock valued at $6,009,566. 0.20% of the stock is currently owned by company insiders.

GSK Stock Down 0.2%

GSK stock opened at GBX 1,853 on Wednesday. The stock's fifty day simple moving average is GBX 1,886.30 and its two-hundred day simple moving average is GBX 1,945.14. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 1-year low of GBX 1,590.50 and a 1-year high of GBX 2,282. The stock has a market cap of £74.25 billion, a P/E ratio of 15.73, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts expect that GSK will post 175.980975 EPS for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.